secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0000950170-24-133693
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025
--------------------------------------------------------------------------------

- R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.
- FDA accepted NDA for oral on-demand HAE treatment sebetralstat; PDUFA date June 17, 2025.
- MAA submissions in UK, Switzerland, Australia, Singapore via Access Consortium; EMA MAA validated in August.
- Appointed Brian Piekos as CFO; raised $160M total via synthetic royalty financing and equity offerings.
- New data presented at ACAAI and HAEi Global Angioedema Forum supporting early attack treatment and anxiety reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024133693/0000950170-24-133693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024133693/kalv-20241205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-133693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer